Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second Meningococcal C conjugate vaccine dose timing in children
2011-000375-13Phase 4Completed
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Feb 2011
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Meningococcal group C polysaccharide conjugate vaccine in invasive meningococcal disease (IMD) (3 cohorts), sponsored by National Institute for Public Health and the Environment. Primary endpoint: MenC-PS specific IgG and SBA levels at 1 month and 1 year post-vaccination. Started Feb 2011; status: completed.
02
Drugs
Meningococcal group C polysaccharide conjugate vaccine
03
Conditions
invasive meningococcal disease (IMD)
Beyond the preview
Go deeper on 2011-000375-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000375-13.